Analyst Ami Fadia from Needham maintained a Buy rating on Merus (MRUS – Research Report) and keeping the price target at $83.00.
Ami Fadia has given his Buy rating due to a combination of factors that highlight Merus’s promising position in the healthcare sector. The company’s ongoing pivotal studies in head and neck squamous cell carcinoma (HNSCC) are particularly noteworthy, as they aim to establish a best-in-class asset with their combination therapy of petosemtamab and pembrolizumab in first-line PD-L1 positive recurrent/metastatic HNSCC, as well as petosemtamab monotherapy in second and third-line settings.
Furthermore, the anticipated updates on clinical data for these therapies are expected to provide significant insights into their efficacy. The upcoming data release in the first half of 2025 for the Phase 2 study of peto + pembro in first-line PD-L1+ r/m HNSCC, along with initial clinical data for peto in metastatic colorectal cancer (mCRC) in the second half of 2025, are key milestones that could enhance Merus’s market position and validate the potential of their therapeutic assets.
Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Blueprint Medicines. According to TipRanks, Fadia has an average return of -2.9% and a 37.04% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $110.00 price target.